BOSTON SCIENTIFIC CORP (BSX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-11

Key Insights

Director Zane Ellen M received an annual equity award of 3,800 restricted shares (valued at $215,000) vesting at the next stockholders' meeting, indicating standard board compensation practices and confidence in future stock performance.
The acquisition was granted at $0.00 transaction price, confirming this is a restricted stock award rather than a market purchase, which is typical for non-officer director compensation.
Post-transaction beneficial ownership stands at 27,934 shares held directly, representing a meaningful personal stake in BSX by a board member and suggesting aligned interests with shareholders.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-11

Director David Wichmann acquired 3,800 shares of BSX common stock on 05/07/2026 at no cost as part of an annual equity award, representing a $215,000 compensation component valued at the grant date closing price.
The restricted stock grant vests in full upon the next annual stockholder meeting, indicating standard director compensation practices rather than market-driven trading activity.
Wichmann's total beneficial ownership increased to 45,382 shares following this transaction, demonstrating ongoing alignment between director interests and shareholder value.

Filed: 2026-05-11

Director Christophe Pierre Weber received a total of 2,907 shares in restricted stock awards (1,767 + 1,140 shares) on 05/07/2026, valued at approximately $315,500, representing standard annual non-employee director compensation rather than discretionary insider buying.
An additional 2,660 deferred stock units were granted, bringing total equity compensation to approximately $466,000, which vests upon the next annual stockholder meeting and will be issued post-separation from the board, indicating routine director compensation practices.
All securities were acquired at $0.0000 transaction price, confirming these are compensation grants rather than open market purchases, with no indication of insider confidence regarding stock valuation through personal buying.
The reporting person holds 3,786 shares of common stock directly and 2,660 deferred stock units following these transactions, representing a modest equity stake typical for non-employee board directors without significant personal investment.

Filed: 2026-05-11

Director Cathy R Smith acquired 6,009 deferred stock units (3,800 + 2,209) on 05/07/2026, representing total equity compensation of approximately $340,000 ($215,000 + $125,000), indicating standard director compensation practices.
The acquisition consists of two components: an annual equity award ($215,000 value) and a cash retainer substitute in DSU form ($125,000 value), both vesting at the next annual stockholder meeting with share issuance deferred until separation from board service.
All acquired securities are held directly (Direct ownership) in deferred form rather than immediate equity, suggesting compliance with standard non-employee director compensation plans rather than insider confidence signals about future stock performance.

Filed: 2026-05-11

Director Pegus Cheryl acquired 5,081 deferred stock units (DSUs) on 05/07/2026, valued at approximately $287,500 total, representing a routine annual equity compensation grant and committee chair retainer.
The DSUs vest upon the next annual stockholder meeting and will be converted to common shares following the director's separation from the board, indicating standard non-employee director compensation practices with no concerning timing.
Total beneficial ownership increased to 10,998 DSUs following these transactions, demonstrating continued alignment between director and shareholder interests through equity-based compensation.
The filing shows no material insider selling pressure, with acquisitions limited to standard annual compensation arrangements rather than discretionary open-market purchases.

Filed: 2026-05-11

Director Susan Morano acquired 5,081 shares total (3,800 restricted shares from annual equity award + 1,281 restricted shares in lieu of cash compensation) on 05/07/2026, bringing her total beneficial ownership to 11,744 shares.
Both equity awards vest upon the next annual stockholder meeting, indicating the company uses performance-aligned compensation structures for board members rather than immediate cash compensation.
The restricted stock grants totaling approximately $287,500 in value ($215,000 annual award + $72,500 cash-in-lieu grant) represent standard director compensation at Boston Scientific, with no indication of insider selling or portfolio liquidation.

Filed: 2026-05-11

Director Jessica L. Mega acquired 3,800 shares of BSX common stock on 05/07/2026 at $0.00 price, representing an annual equity award valued at $215,000 based on the closing price at grant date.
The restricted stock award vests in full at the next annual stockholders meeting, indicating standard director compensation practices rather than open market purchases or discretionary buying activity.
Following this transaction, Mega's total beneficial ownership increased to 12,035 shares held directly, demonstrating continued alignment with company shareholders through equity holdings.

Filed: 2026-05-11

Director Edward Ludwig acquired 3,800 shares of Boston Scientific common stock on 05/07/2026 through an annual equity award in the form of restricted stock, valued at approximately $215,000 based on closing price at grant.
The restricted stock award vests in full upon the next annual stockholder meeting, indicating standard director compensation practices with performance-linked retention incentives.
Post-transaction beneficial ownership stands at 21,779 shares held directly, representing a modest equity stake and demonstrating continued insider alignment with shareholder interests.

Filed: 2026-05-11

Director David C. Habiger acquired 3,800 shares of BSX common stock on 05/07/2026 through an annual equity award valued at $215,000, reflecting ongoing board compensation practices.
The restricted stock grant vests in full at the next annual stockholders meeting, indicating standard director incentive alignment with shareholder interests.
Post-transaction beneficial ownership stands at 9,428 shares held directly, suggesting moderate personal investment by the director in the company.

Filed: 2026-03-03

Insider Emily Woodworth, SVP and Global Controller, exercised 838 restricted stock units and sold 372 shares of Boston Scientific common stock on March 1, 2026.
The transaction resulted in Woodworth directly owning 2,859 shares of Boston Scientific, down from 3,231 shares prior to the transaction.
Insiders' transactions can provide signals about a company's future prospects, and should be monitored by investors.

Filed: 2026-02-27

The reporting person, Arthur C. Butcher, who is an EVP & Grp Pres at Boston Scientific Corp, acquired 6,851 shares of common stock through the company's 401(k) Retirement Savings Plan, indicating their confidence in the company's performance.
The reporting person still holds a significant direct ownership of 55,792 shares, suggesting they remain invested in the long-term success of Boston Scientific Corp.
The acquisition of shares through the 401(k) plan indicates the reporting person's commitment to the company and their belief in its growth potential.

Other reports for BOSTON SCIENTIFIC CORP

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.